Literature DB >> 25542262

Novel oral anticoagulants in patients undergoing cardioversion for atrial fibrillation.

Alexandros Briasoulis1, Anupama Kottam, Mazhar Khan, Luis Afonso.   

Abstract

Recent trials on novel oral anticoagulants (NOAC) in patients undergoing cardioversion showed that NOACs are as safe and effective as treatment with vitamin K antagonists in patients with atrial fibrillation undergoing electric or pharmacological cardioversion. We conducted an EMBASE and MEDLINE search for studies in which patients undergoing cardioversion were assigned to treatment with NOACs versus VKAs. We identified one prospective randomized study and three post hoc analysis of randomized trials which enrolled 2,788 controls that received NOACs and 1,729 patients that received VKAs. NOACs and VKAs had comparable effects on the rates of stroke/thromboembolism, major bleeding events and all-cause mortality. NOACs are safe and effective alternatives to VKA in patients with AF undergoing cardioversion.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25542262     DOI： 10.1007/s11239-014-1161-7

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


  9 in total

Review 1.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2014-03-28       Impact factor: 24.094

2.  Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion.

Authors:  Rangadham Nagarakanti; Michael D Ezekowitz; Jonas Oldgren; Sean Yang; Michael Chernick; Timothy H Aikens; Greg Flaker; Josep Brugada; Gabriel Kamensky; Amit Parekh; Paul A Reilly; Salim Yusuf; Stuart J Connolly
Journal:  Circulation       Date:  2011-01-03       Impact factor: 29.690

3.  Impact of electrical cardioversion for atrial fibrillation on left atrial appendage function and spontaneous echo contrast: characterization by simultaneous transesophageal echocardiography.

Authors:  R A Grimm; W J Stewart; J D Maloney; G I Cohen; G L Pearce; E E Salcedo; A L Klein
Journal:  J Am Coll Cardiol       Date:  1993-11-01       Impact factor: 24.094

4.  Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation.

Authors:  Riccardo Cappato; Michael D Ezekowitz; Allan L Klein; A John Camm; Chang-Sheng Ma; Jean-Yves Le Heuzey; Mario Talajic; Maurício Scanavacca; Panos E Vardas; Paulus Kirchhof; Melanie Hemmrich; Vivian Lanius; Isabelle Ling Meng; Peter Wildgoose; Martin van Eickels; Stefan H Hohnloser
Journal:  Eur Heart J       Date:  2014-09-02       Impact factor: 29.983

5.  Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation.

Authors:  A L Klein; R A Grimm; R D Murray; C Apperson-Hansen; R W Asinger; I W Black; R Davidoff; R Erbel; J L Halperin; D A Orsinelli; T R Porter; M F Stoddard
Journal:  N Engl J Med       Date:  2001-05-10       Impact factor: 91.245

6.  Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation).

Authors:  Greg Flaker; Renato D Lopes; Sana M Al-Khatib; Antonio G Hermosillo; Stefan H Hohnloser; Brian Tinga; Jun Zhu; Puneet Mohan; David Garcia; Jozef Bartunek; Dragos Vinereanu; Steen Husted; Veli Pekka Harjola; Marten Rosenqvist; John H Alexander; Christopher B Granger
Journal:  J Am Coll Cardiol       Date:  2013-11-06       Impact factor: 24.094

7.  Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter.

Authors:  A Z Arnold; M J Mick; R P Mazurek; F D Loop; R G Trohman
Journal:  J Am Coll Cardiol       Date:  1992-03-15       Impact factor: 24.094

8.  Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial.

Authors:  Jonathan P Piccini; Susanna R Stevens; Yuliya Lokhnygina; Manesh R Patel; Jonathan L Halperin; Daniel E Singer; Graeme J Hankey; Werner Hacke; Richard C Becker; Christopher C Nessel; Kenneth W Mahaffey; Keith A A Fox; Robert M Califf; Günter Breithardt
Journal:  J Am Coll Cardiol       Date:  2013-03-14       Impact factor: 24.094

9.  The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.

Authors:  Julian P T Higgins; Douglas G Altman; Peter C Gøtzsche; Peter Jüni; David Moher; Andrew D Oxman; Jelena Savovic; Kenneth F Schulz; Laura Weeks; Jonathan A C Sterne
Journal:  BMJ       Date:  2011-10-18
  9 in total
  2 in total

1.  Evaluating cardioversion outcomes for atrial fibrillation on novel oral anticoagulants versus warfarin: experience at a tertiary referral centre.

Authors:  Z Sharif; B Srinivas; I Tiedt; N Ryan; M Awadalla; V Sullivan; D P Foley; T Gumbrielle; B McAdam; R G Sheahan
Journal:  Ir J Med Sci       Date:  2017-02-24       Impact factor: 1.568

2.  Croatia needs a registry of patients undergoing direct current cardioversion for persistent atrial fibrillation/flutter.

Authors:  Mia Dubravčić; Petra Cukon; Siniša Car; Davor Puljević; Vladimir Trkulja
Journal:  Croat Med J       Date:  2016-08-31       Impact factor: 1.351
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.